Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04759339 · ClinicalTrials.gov registry record · Phase 1
An Open Label, Study of the Systemic Exposure to Articaine After Topical Ocular Dosing of AG-920
A Phase 1 study, sponsored by American Genomics.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT04759339 is a Phase 1 study that has completed, run by American Genomics. The registered enrollment target is 14 participants.
The verdict
NCT04759339, a Phase 1 study, has completed, sponsored by American Genomics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, non-comparative study in healthy subjects performed in the US. It is designed to assess systemic exposure to articaine and its metabolite articainic acid after dosing a single topical ocular administration of AG-920 in the randomized study eye.
Interventions
- DRUG AG-920
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-02-24 |
| Est. Completion | 2021-02-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04759339
The ClinicalTrials.gov registry entry for NCT04759339 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is American Genomics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AG-920 is the first listed.
NCT04759339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04759339 about?
NCT04759339 is a clinical study titled "An Open Label, Study of the Systemic Exposure to Articaine After Topical Ocular Dosing of AG-920". This is a Phase 1, open-label, non-comparative study in healthy subjects performed in the US. It is designed to assess systemic exposure to articaine and its metabolite articainic acid after dosing a single topical ocular administration of AG-920 in the randomized study eye.
What is the current status of trial NCT04759339?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2021-02-24. Estimated completion is 2021-02-25.
What interventions are being tested in trial NCT04759339?
The interventions under investigation include: AG-920 (DRUG).
Who is sponsoring clinical trial NCT04759339?
This trial is sponsored by American Genomics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.